nach oben

Annals of Nuclear Medicine

Erschienen in:

04.08.2016 | Original Article

Dual-time-point ¹⁸F-FDG PET/CT in the diagnosis of solitary pulmonary lesions in a region with endemic granulomatous diseases

verfasst von: Yu-Erh Huang, Yu-Jie Huang, Mary Ko, Chien-Chin Hsu, Chih-Feng Chen

Erschienen in: Annals of Nuclear Medicine | Ausgabe 9/2016

Einloggen, um Zugang zu erhalten

Abstract

Objective

Granulomatous diseases (GDs) can be metabolically active and indistinguishable from lung cancer on ¹⁸F-fluorodeoxyglucose positron emission tomography (¹⁸F-FDG PET) imaging. Evaluation of solitary pulmonary lesions remains a diagnostic challenge in regions with endemic GD. This study sought to determine the efficacy of dual-time-point (DTP) ¹⁸F-FDG PET/computed tomography (CT) imaging in diagnosing solitary pulmonary lesions from such regions.

Methods

A total of 50 patients with solitary pulmonary nodules or masses with confirmed histopathological diagnoses underwent DTP ¹⁸F-FDG PET/CT imaging at 1 and 3 h after tracer injection. The maximum standardized uptake value (SUV_max) on early and delayed scans (SUV_1h and SUV_3h, respectively) and retention index (RI) were calculated for each pulmonary lesion. Receiver operating characteristic analysis was performed to evaluate the discriminating validity of the parameters.

Results

There were 37 malignant and 13 benign solitary pulmonary lesions. Eight of the 13 (62 %) benign lesions were GDs. The sensitivity/specificity/accuracy of SUV_1h, SUV_3h and RI were 84/69/80 %, 84/85/84 %, and 81/54/74 %, respectively. SUV_3h had the best diagnostic performance, especially regarding specificity. The values of SUV_1h and SUV_3h were significantly different between malignant lesions and GD, while the RI values of malignant lesions and GD were both high (18.6 ± 19.5 and 18.7 ± 15.3 %, respectively; P = not significant).

Conclusion

SUV_3h appeared to improve the diagnostic specificity of ¹⁸F-FDG PET/CT in evaluating solitary pulmonary lesions from regions with endemic GD.

Gupta NC, Frank AR, Dewan NA, Redepenning LS, Rothberg ML, Mailliard JA, et al. Solitary pulmonary nodules: detection of malignancy with PET with 2-[F-18]-fluoro-2-deoxy-d-glucose. Radiology. 1992;184:441–4.CrossRefPubMed

Patz EF Jr, Lowe VJ, Hoffman JM, Paine SS, Burrowes P, Coleman RE, et al. Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology. 1993;188:487–90.CrossRefPubMed

Dewan NA, Gupta NC, Redepenning LS, Phalen JJ, Frick MP. Diagnostic efficacy of FDG-PET imaging in solitary pulmonary nodules. Potential role in evaluation and management. Chest. 1993;104:997–1002.CrossRefPubMed

Flier JS, Mueckler MM, Usher P, Lodish HF. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science. 1987;235:1492–5.CrossRefPubMed

Monakhov NK, Neistadt EL, Shavlovskil MM, Shvartsman AL, Neifakh SA. Physicochemical properties and isoenzyme composition of hexokinase from normal and malignant human tissues. J Natl Cancer Inst. 1978;61:27–34.PubMed

Gould MK, Maclean CC, Kuschner WG, Rydzak CE, Owens DK. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA. 2001;285:914–24.CrossRefPubMed

Kapucu LO, Meltzer CC, Townsend DW, Keenan RJ, Luketich JD. Fluorine-18-fluorodeoxyglucose uptake in pneumonia. J Nucl Med. 1998;39:1267–9.PubMed

Goo JM, Im JG, Do KH, Yeo JS, Seo JB, Kim HY, et al. Pulmonary tuberculoma evaluated by means of FDG PET: findings in 10 cases. Radiology. 2000;216:117–21.CrossRefPubMed

Igai H, Gotoh M, Yokomise H. Computed tomography (CT) and positron emission tomography with [¹⁸F]fluoro-2-deoxy-d-glucose (FDG-PET) images of pulmonary cryptococcosis mimicking lung cancer. Eur J Cardiothorac Surg. 2006;30:837–9.CrossRefPubMed

10.

Duhaylongsod FG, Lowe VJ, Patz EF Jr, Vaughn AL, Coleman RE, Wolfe WG. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET). J Thorac Cardiovasc Surg. 1995;110:130–9.CrossRefPubMed

11.

Deppen S, Putnam JB Jr, Andrade G, Speroff T, Nesbitt JC, Lambright ES, et al. Accuracy of FDG-PET to diagnose lung cancer in a region of endemic granulomatous disease. Ann Thorac Surg. 2011;92:428–32.CrossRefPubMedPubMedCentral

12.

Sebro R, Aparici CM, Hernandez-Pampaloni M. FDG PET/CT evaluation of pathologically proven pulmonary lesions in an area of high endemic granulomatous disease. Ann Nucl Med. 2013;27:400–5.CrossRefPubMedPubMedCentral

13.

Lodge MA, Lucas JD, Marsden PK, Cronin BF, O’Doherty MJ, Smith MA. A PET study of ¹⁸FDG uptake in soft tissue masses. Eur J Nucl Med. 1999;26:22–30.CrossRefPubMed

14.

Xiu Y, Bhutani C, Dhurairaj T, Yu JQ, Dadparvar S, Reddy S, et al. Dual-time point FDG PET imaging in the evaluation of pulmonary nodules with minimally increased metabolic activity. Clin Nucl Med. 2007;32:101–5.CrossRefPubMed

15.

Laffon E, de Clermont H, Begueret H, Vernejoux JM, Thumerel M, Marthan R, et al. Assessment of dual-time-point ¹⁸F-FDG-PET imaging for pulmonary lesions. Nucl Med Commun. 2009;30:455–61.CrossRefPubMed

16.

Matthies A, Hickeson M, Cuchiara A, Alavi A. Dual time point ¹⁸F-FDG PET for the evaluation of pulmonary nodules. J Nucl Med. 2002;43:871–5.PubMed

17.

Macdonald K, Searle J, Lyburn I. The role of dual time point FDG PET imaging in the evaluation of solitary pulmonary nodules with an initial standard uptake value less than 2.5. Clin Radiol. 2011;66:244–50.CrossRefPubMed

18.

Cloran FJ, Banks KP, Song WS, Kim Y, Bradley YC. Limitations of dual time point PET in the assessment of lung nodules with low FDG avidity. Lung Cancer. 2010;68:66–71.CrossRefPubMed

19.

Chen CJ, Lee BF, Yao WJ, Cheng L, Wu PS, Chu CL, et al. Dual-phase ¹⁸F-FDG PET in the diagnosis of pulmonary nodules with an initial standard uptake value less than 2.5. Am J Roentgenol. 2008;191:475–9.CrossRef

20.

Sathekge MM, Maes A, Pottel H, Stoltz A, van de Wiele C. Dual time-point FDG PET-CT for differentiating benign from malignant solitary pulmonary nodules in a TB endemic area. S Afr Med J. 2010;100:598–601.CrossRefPubMed

21.

Lin YY, Chen JH, Ding HJ, Liang JA, Yeh JJ, Kao CH. Potential value of dual-time-point ¹⁸F-FDG PET compared with initial single-time-point imaging in differentiating malignant from benign pulmonary nodules: a systematic review and meta-analysis. Nucl Med Commun. 2012;33:1011–8.CrossRefPubMed

22.

Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International association for the study of lung cancer/American thoracic society/European respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6:244–85.CrossRefPubMedPubMedCentral

23.

Cook GJ, Wegner EA, Fogelman I. Pitfalls and artifacts in ¹⁸FDG PET and PET/CT oncologic imaging. Semin Nucl Med. 2004;34:122–33.CrossRefPubMed

24.

Schisterman EF, Perkins NJ, Liu A, Bondell H. Optimal cut-point and its corresponding Youden Index to discriminate individuals using pooled blood samples. Epidemiology. 2005;16:73–81.CrossRefPubMed

25.

Suga K, Kawakami Y, Hiyama A, Sugi K, Okabe K, Matsumoto T, et al. Dual-time point ¹⁸F-FDG PET/CT scan for differentiation between ¹⁸F-FDG-avid non-small cell lung cancer and benign lesions. Ann Nucl Med. 2009;23:427–35.CrossRefPubMed

26.

Al-Sugair A, Coleman RE. Applications of PET in lung cancer. Semin Nucl Med. 1998;28:303–19.CrossRefPubMed

27.

Fin L, Daouk J, Morvan J, Bailly P, El Esper I, Saidi L, et al. Initial clinical results for breath-hold CT-based processing of respiratory-gated PET acquisitions. Eur J Nucl Med Mol Imaging. 2008;35:1971–80.CrossRefPubMed

28.

Henschke CI, Yankelevitz DF, Mirtcheva R, McGuinness G, McCauley D, Miettinen OS, et al. CT screening for lung cancer: frequency and significance of part-solid and nonsolid nodules. Am J Roentgenol. 2002;178:1053–7.CrossRef

29.

Naidich DP, Bankier AA, MacMahon H, Schaefer-Prokop CM, Pistolesi M, Goo JM, et al. Recommendations for the management of subsolid pulmonary nodules detected at CT: a statement from the Fleischner society. Radiology. 2013;266:304–17.CrossRefPubMed

30.

Tsujikawa T, Otsuka H, Morita N, Saegusa H, Kobayashi M, Okazawa H, et al. Does partial volume corrected maximum SUV based on count recovery coefficient in 3D-PET/CT correlate with clinical aggressiveness of non-Hodgkin’s lymphoma? Ann Nucl Med. 2008;22:23–30.CrossRefPubMed

Titel: Dual-time-point 18F-FDG PET/CT in the diagnosis of solitary pulmonary lesions in a region with endemic granulomatous diseases
verfasst von: Yu-Erh Huang
Yu-Jie Huang
Mary Ko
Chien-Chin Hsu
Chih-Feng Chen
Publikationsdatum: 04.08.2016
Verlag: Springer Japan
Erschienen in: Annals of Nuclear Medicine / Ausgabe 9/2016
Print ISSN: 0914-7187
Elektronische ISSN: 1864-6433
DOI: https://doi.org/10.1007/s12149-016-1109-4

Springer Medizin

Abstract

Objective

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2016

Optimal ROI setting on the anatomically normalized I-123 FP-CIT images using high-resolution SPECT

Cerebral hyperperfusion syndrome resulting in subarachnoid hemorrhage after carotid artery stenting

One year of nuclear cardiology in Europe

Carbidopa-assisted 18F-fluorodihydroxyphenylalanine PET/CT for the localization and staging of non-functioning neuroendocrine pancreatic tumors

Incidental focal 18F-FDG uptake in the frontal process of the maxilla on PET/CT: prevalence and clinical significance

Phase IIa clinical study of [18F]fluciclovine: efficacy and safety of a new PET tracer for brain tumors